Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-29
2011-03-29
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S421000, C514S469000, C514S470000, C548S453000, C549S465000
Reexamination Certificate
active
07915300
ABSTRACT:
A compound of the formula IIwhereinone of R1and R2is halo and the other is H or halo;R3is C1-C4straight or branched chain, optionally fluorinated, alkyl;R4is H; orR3together with R4and the adjoining backbone carbon defines:a spiro-C5-C7cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C1-C4alkyl or C1-C4haloalkyl; or optionally bridged with a methylene group; ora C4-C6saturated heterocycle having a hetero atom selected from O, NRa, S, S(═O)2; where Ra is H, C1-C4alkyl or CH3C(═O);R5is independently selected from H or methyl;E is —C(═O)—, —S(═O)m—, —NR5S(═O)m—, —NR5C(═O)—, —OC(═O)—,R6is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or heterocycle;m is independently 0,1 or 2;are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.
REFERENCES:
patent: 98/50533 (1998-11-01), None
patent: WO 98/50533 (1998-11-01), None
patent: WO 01/58886 (2001-08-01), None
patent: 02/057270 (2002-07-01), None
patent: WO 02/057270 (2002-07-01), None
patent: WO 02057270 (2002-07-01), None
patent: 02/088106 (2002-11-01), None
patent: WO 02/088106 (2002-11-01), None
patent: WO 2005/056529 (2005-06-01), None
patent: WO 2005/065578 (2005-07-01), None
patent: WO 2005/066159 (2005-07-01), None
patent: WO 2005/066180 (2005-07-01), None
patent: WO 2007/006716 (2007-01-01), None
patent: WO 2008/007127 (2008-01-01), None
Preliminary STN search—10584930—02262010.
Wu and Farrelly, Toxicology 236:1-6, 2007.
Third Party Observations filed on behalf of Amura Therapeutics Limited, Jan. 5, 2009.
Applicant's Response to Examination Report in Corresponding European Application, Mar. 2, 2009.
Applicants Cover Letter, Jun. 29, 2007, in European Opposition.
Applicants Cover Letter, Jan. 14, 2008, in European Opposition.
Clyde-Watson et al., Third Party Observations filed on behalf of Amura Therapeutics Limited . . . , Sep. 3, 2007, EPO—Munich.
Teuten et al., Applicant Medivir AB, D4—Supplementary Experimental Data, Jun. 29, 2007, EPO—Munich.
Wolfe et al., Scope and Limitations of the Pd/BINAP-Catalyzed Amination of Aryl Bromides, J. Org. Chem, 2000, vol. 65, pp. 1144-1157.
Watts, et al., “Functionalised 2,3-dimethyl-3-aminotetrahydrofuran-4-one and N-(3-oxo-hexahydrocyclcopenta[b]furan-3a-yl)acylamide based scaffolds: synthesis and cysteinyl proteinase inhibition”, Bioorganic and Medicinal Chemistry, 2004 12:2903-2925.
Quibell, “Bicyclic peptidomimetic tetrahydrofuro[3,2-b]pyrrol-3-one and hexahydrofuro[3,2-b]pyridine-3-one based scaffolds: synthesis and cysteinyl proteinase inhibition”, Bioorganic and Medicinal Chemistry, 2004 12:5689-5710.
International Search Report (Form PCT/ISA/210), 2006.
Written Opinion of the Searching Authority (Form PCT/ISA/237), 2006.
Bonnaud Thierry
Carr Andrew
Classon Bjorn
Crespo Laia
Diaz Victor
Birch, Stewart, Kolasch and Birch LLP
Chu Yong
Medivir AB
LandOfFree
Cysteine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cysteine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cysteine protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2755930